MAIA
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.13 | $0 | -$7M |
| 2026 Q1 | -0.14 | $0 | -$5M |
| 2025 Q4 | -0.09 | $0 | -$7M |
| 2025 Q3 | -0.27 | $0 | -$3M |
| 2025 Q2 | -0.18 | $0 | -$4M |
| 2025 Q1 | -0.16 | $0 | -$4M |
| 2024 Q4 |
| -0.14 |
| $0 |
| -$4M |
| 2024 Q3 | -0.11 | $0 | -$4M |